
16 November 2026
("EDX Medical" or the "Company")
'Bed & ISA' share transfer & share purchase
CAMBRIDGE, UK: EDX Medical Group plc, which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, announces the Company was notified today that on 13 November 2026 Dr Michael Hudson, Chief Executive Officer and Director of the company, performed a 'Bed and ISA' transfer.
Dr Michael Hudson sold 193,439 ordinary shares of 1p from his share dealing account at a price of 7.75 pence per share and purchased 193,568 into his ISA account at a price of 7.75 pence per share.
As a result, Dr Michael Hudson's total interest in the Company is 20,750,129 representing 4.81% of the total voting rights of the Company.
|
1 |
Details of PDMR / person closely associated with them (“PCA”) | ||||||||||
|
(a) |
Name |
Dr Michael Hudson | |||||||||
|
2 |
Reason for the notification | ||||||||||
|
(a) |
Position/status |
PDMR / CEO | |||||||||
|
(b) |
Initial notification/amendment |
Initial Notification | |||||||||
|
3 |
Details of the Issuer | ||||||||||
|
(a) |
Name |
EDX Medical Group plc | |||||||||
|
(b) |
Legal Entity Identifier code |
213800BZVJZTMCZ6DJ63 | |||||||||
|
4 |
Details of the transaction(s)
| ||||||||||
|
(a) |
Description of the financial instrument |
Ordinary shares of £0.01 each | |||||||||
|
(b) |
Identification Code |
ISIN: GB00BNDMJS47 | |||||||||
|
(c) |
Nature of the transaction |
| |||||||||
|
(d) |
Currency |
GBP | |||||||||
|
(e) |
Price(s) and volume(s) |
| |||||||||
|
(f) |
Aggregated information - Aggregated volume - Price |
n/a
| |||||||||
|
(g) |
Date of the transaction |
13-11-2026 | |||||||||
|
(h) |
Place of the transaction |
XLON:AIMX | |||||||||
|
Contacts: |
| |
|
|
| |
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
|
Stuart Andrews |
+44 (0) 20 7523 8318 |
|
|
Media House International |
| |
|
Ramsay Smith
Gary McQueen |
+44 (0)7788 414856 + 44 (0)7834 694609 | |
|
IFC Advisory (Investor Relations) |
| |
|
Tim Metcalfe Graham Herring |
+44 (0) 203 934 6630 | |
|
|
|
|
Notes for Editors:
About EDX Medical Group plc
The EDX Medical Group plc is listed on the AIM market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.